AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio

Study Shows 73% Reduction in LDL Cholesterol

 
• By Andrew McConaghie
Ionis HQ
The candidate is the latest to come out of Ionis' antisense oligonucleotide pipeline, and could be a strong challenger to Novartis's Leqvio. • Source: Ionis

More from Business

More from Scrip